School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Acta Pharmacol Sin. 2013 Oct;34(10):1325-36. doi: 10.1038/aps.2013.47. Epub 2013 Jul 15.
des-O-methyllasiodiplodin (DML) from Cerbera manghas has shown antagonistic activity against mineralocorticoid receptor (MR). Considering the involvement of MR in the insulin tolerance, we attempted to investigate the potential of DML in the treatment of type 2 diabetes mellitus (T2DM).
Surface plasmon resonance (SPR) technology and reporter gene-based assays were used to study protein-small molecule interactions. HepG2 and 3T3-L1 cells were treated with H2O2 (0.2 mmol/L) or aldosterone (10 nmol/L) for 24 h. The expression of MR in the cells was downregulated with siRNA. The anti-inflammatory effect of the compound was evaluated, respectively. db/db mice were administered DML (30 mg·kg(-1)·d(-1)) for 4 weeks. Serum biochemical parameters and insulin sensitivity were examined. The expression levels of pro-inflammatory cytokines (MCP-1, TNF-α and IL-6) and ROS-related genes (NADPH p47 subunit and transcriptional factor PU.1) in adipose tissues and livers were analyzed using real-time RT-PCR.
In HepG2 and 3T3-L1 cells, both H2O2 and aldosterone markedly stimulates the expression of MCP-1, TNFα, IL-6, p47 and PU.1 genes. Co-treatment with DML (10 μmol/L) significantly reduced the H2O2- or aldosterone-induced expression of these genes. SPR-based assay confirmed the antagonistic activity of DML against the interaction between SRC-1 and MR-LBD. Furthermore, DML decreased aldosterone-induced MR transcriptional activity in a dose-dependent manner. Downregulation of MR with siRNA in the cells prevented or significantly attenuated aldosterone-stimulated expression of these genes, whereas DML did no longer affect the expression of these genes except that of IL-6. Oral administration of DML effectively reduced the levels of blood glucose and glycosylated hemoglobin (HbA1c) in db/db mice. The treatment also rectified the expression of pro-inflammatory factor and ROS-related genes in db/db mice.
DML effectively lowers the blood glucose level in db/db mice possibly via ameliorating the expression of obesity-related pro-inflammatory cytokines, highlighting the potential of the marine natural product as a drug lead for the treatment of metabolic disorders.
来自 Cerbera manghas 的 des-O-methyllasiodiplodin(DML)已显示出对盐皮质激素受体(MR)的拮抗活性。考虑到 MR 在胰岛素耐受中的作用,我们试图研究 DML 在治疗 2 型糖尿病(T2DM)中的潜力。
表面等离子体共振(SPR)技术和基于报告基因的测定用于研究蛋白质-小分子相互作用。用 H2O2(0.2mmol/L)或醛固酮(10nmol/L)处理 HepG2 和 3T3-L1 细胞 24 小时。用 siRNA 下调细胞中 MR 的表达。分别评估化合物的抗炎作用。db/db 小鼠给予 DML(30mg·kg(-1)·d(-1))4 周。检查血清生化参数和胰岛素敏感性。使用实时 RT-PCR 分析脂肪组织和肝脏中促炎细胞因子(MCP-1、TNF-α和 IL-6)和 ROS 相关基因(NADPH p47 亚基和转录因子 PU.1)的表达水平。
在 HepG2 和 3T3-L1 细胞中,H2O2 和醛固酮均显著刺激 MCP-1、TNFα、IL-6、p47 和 PU.1 基因的表达。用 DML(10μmol/L)共同处理可显著降低 H2O2 或醛固酮诱导的这些基因的表达。基于 SPR 的测定证实了 DML 对 SRC-1 和 MR-LBD 之间相互作用的拮抗活性。此外,DML 以剂量依赖性方式降低醛固酮诱导的 MR 转录活性。用 siRNA 下调细胞中的 MR 可阻止或显著减弱醛固酮刺激的这些基因的表达,而 DML 除了 IL-6 外,不再影响这些基因的表达。口服 DML 可有效降低 db/db 小鼠的血糖和糖化血红蛋白(HbA1c)水平。该治疗还纠正了 db/db 小鼠中促炎因子和 ROS 相关基因的表达。
DML 可有效降低 db/db 小鼠的血糖水平,可能是通过改善肥胖相关促炎细胞因子的表达,突显了海洋天然产物作为治疗代谢紊乱药物的潜在用途。